Cenobamate Dose Titration
Start cenobamate at 12.5 mg once daily and increase by 12.5-25 mg every 2 weeks, targeting a maintenance dose of 200 mg/day, with a maximum of 400 mg/day if needed for seizure control. 1
Recommended Titration Schedule
The FDA-approved titration protocol is structured as follows 1:
- Week 1-2: 12.5 mg once daily
- Week 3-4: 25 mg once daily
- Week 5-6: 50 mg once daily
- Week 7-8: 100 mg once daily
- Week 9-10: 150 mg once daily
- Week 11-12: 200 mg once daily (typical maintenance dose)
If additional seizure control is needed, continue increasing by 50 mg every 2 weeks up to a maximum of 400 mg/day 1.
Clinical Evidence Supporting This Approach
This slow titration schedule was specifically designed to mitigate the risk of DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms), which occurred in 3 cases during early clinical development with faster titration 2. The start-low (12.5 mg/day), go-slow approach eliminated DRESS cases in 1,339 patients in the large Phase 3 open-label safety study 2.
Real-world data from Asian populations confirms that significant seizure reductions occur early during titration: patients experienced a 42.9% median reduction in seizure frequency by weeks 5-6 (at 50 mg/day) and 55.6% reduction by weeks 7-8 (at 100 mg/day), with 26.7% achieving seizure freedom at 100 mg/day 3. This demonstrates that therapeutic benefit begins well before reaching the target maintenance dose.
Critical Dosing Considerations
Drug Interactions Requiring Dose Adjustments
Phenytoin or phenobarbital co-administration: These patients require special management because cenobamate inhibits CYP2C19 and will increase phenytoin/phenobarbital levels 1, 2. During cenobamate titration, reduce phenytoin or phenobarbital doses by 25-33% to maintain stable plasma levels 2. Do not adjust cenobamate titration rate or other concomitant antiseizure medications during this period 2.
Severe renal impairment (CrCl <30 mL/min): Reduce the dose, though specific adjustments are not fully detailed in the provided evidence 1.
Pharmacokinetic Profile
Cenobamate has a 50-60 hour half-life, allowing once-daily dosing 1. Steady-state concentrations are reached after approximately 2 weeks of consistent dosing 1. The drug is at least 88% absorbed orally, with food having no clinically significant effect 1.
Maintenance Dosing
Target maintenance dose: 200 mg once daily 1. This dose achieved a median 78.3% reduction in seizure frequency with a 30.1% seizure-free rate in the pivotal Asian study 4.
Maximum dose: 400 mg once daily for patients requiring additional seizure control 1. At this dose, patients achieved a 100% median reduction in seizure frequency during the maintenance phase with a 52.4% seizure-free rate 4.
Common Pitfalls to Avoid
Do not start at higher doses or titrate faster than recommended - Early clinical trials used 50 mg starting doses with weekly increases, which led to DRESS cases 2. The current 12.5 mg start with biweekly increases is essential for safety.
Do not forget phenytoin/phenobarbital dose reductions - Failure to reduce these medications by 25-33% during cenobamate titration will result in toxicity from elevated phenytoin/phenobarbital levels 2.
Monitor for dose-dependent adverse effects - Dizziness (23.6%) and somnolence (28.1%) are the most common side effects and are dose-related 2, 4. These typically occur during titration and may improve with continued treatment.
Recognize that therapeutic effects begin early - Patients may experience significant seizure reduction at doses as low as 50-100 mg/day 3, so do not assume the full 200 mg target is always necessary.
Pediatric Considerations
While cenobamate is FDA-approved only for adults, emerging real-world evidence in children shows a median initiation dose of 0.3 mg/kg/day with a median final dose of 2.34 mg/kg/day 5. However, this is off-label use and should only be considered in specialized epilepsy centers for drug-resistant cases.